Experimental triple therapy targets tough childhood liver cancer

NCT ID NCT07188311

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing a combination of three drugs—pucotenlimab (an immunotherapy), lenvatinib (a targeted therapy), and irinotecan (chemotherapy)—in children aged 2-18 with advanced or relapsed/refractory hepatoblastoma, a rare liver cancer. The goal is to see if this combination can control the disease or slow its progression. The trial plans to enroll 24 participants who have already tried at least one prior treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pucotenlimab (an immunotherapy drug) combined with lenvatinib (a targeted therapy) and irinotecan (chemotherapy)
What this could lead to: If successful, this combination could offer a new treatment option for children with hard-to-treat liver cancer that has not responded to standard therapy.
What could go wrong: This is a small, early-phase study with only 24 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood malignant neoplasm hepatoblastoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOBLASTOMA PEDIATRIC CANCER

Contacts and locations

Locations

Yizhuo Zhang
RECRUITING

Guangdong, Guangzhou, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.